Evidence map›Paper›PMID 33561512›Full record

ReviewDrug discovery today2021

Bio-inspired nanomaterials as novel options for the treatment of cardiovascular disease.

Rajendran Jc Bose, Khan Ha, Jason R McCarthy

Open access · bronzeAbstract readReview
In one paragraph

Review in Drug discovery today, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.7field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 27 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Biomimetic cell membrane-coated poly(lactic-Bioengineering & translational medicine · 2023
    Review
  6. Review
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Rajendran Jc BoseDepartment of Biomedical Research and Translational Medicine, Masonic Medical Research Institute, Utica, NY, USA.
Khan HaDepartment of Biomedical Research and Translational Medicine, Masonic Medical Research Institute, Utica, NY, USA.
Jason R McCarthyDepartment of Biomedical Research and Translational Medicine, Masonic Medical Research Institute, Utica, NY, USA. Electronic address: jmccarthy@mmri.edu.
Masonic Medical Research Laboratory · US

Funding

The Role of RhoA in the Molecular Pathogenesis of Heart DiseaseR01HL102368 · NHLBI · MASONIC MEDICAL RESEARCH LABORATORY, INC · PI KONTARIDIS, MARIA I · 2010 to 2021
$5.1M
Targeted inhibition of fibrosis for the prevention of heart failureR01HL122238 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI MCCARTHY, JASON R. · 2015 to 2019
$4.0M
Targeting Cell-specific Functions of the Rho Kinase Pathway in Pulmonary FibrosisR01HL133153 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI MCCARTHY, JASON R., MEDOFF, BENJAMIN DAVID · 2016 to 2019
$2.7M
The Monocyte/Macrophage Role in Experimental Deep Vein Thrombosis Resolution and Vein Wall InjuryR01HL144550 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI HENKE, PETER K · 2020 to 2023
$2.2M
Regulatroy Role of HDAC in Post-MI Ventricular RemodelingI01BX002327 · VA · RALPH H JOHNSON VA MEDICAL CENTER · PI MENICK, DONALD R. · 2015 to 2023
–
BLRD VA I01 BX002327NHLBI NIH HHS R01 HL102368NHLBI NIH HHS R01 HL122238NHLBI NIH HHS R01 HL133153NHLBI NIH HHS R01 HL144550
6 · The paper itself

Abstract

Cardiovascular disease (CVD) and its sequelae have long been the leading causes of death and disability in the developed world. Although mortality associated with CVD has been decreasing, due in large part to novel therapeutic options, the rate of decrease has flattened. Thus, there is a great need to investigate alternate therapeutic strategies that can increase efficacy while decreasing adverse effects. Nanomaterials have been widely investigated and have emerged as promising tools for both therapeutic and diagnostic purposes in oncology; however, the potential of nanomaterials has not been extensively explored for cardiovascular medicine. In this review, we focus on recent developments in the field of nanomedicines targeted for CVDs, with a special emphasis on cell membrane-coated nanoparticles (NPs) and their applications.

Indexed as

Drug Delivery SystemsNanoparticlesAnimalsCardiovascular DiseasesCell MembraneHumansNanomedicineNanostructures

Identifiers

PMID33561512
PMCPMC8205945
OpenAlexW3128155550

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.